Arcturus Therapeutics Holdings Inc.ARCTNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank21
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P21
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2025-12.77%
2024-0.09%
202314.76%
202211.15%
202165.03%
202098.37%
2019-38.48%
2018171.82%
201741.35%
20167.31%